Correspondingly, mutations in the N-terminal half of CCDC22 that have been found in XLID patients do not impair myc-CCDC22 binding to VPS33B/VIPAR (Fig. 3B). This evidence concerns the gene MYC and cask-related x-linked intellectual disability.